Back

Amgen Inc

Ticker: AMGN ISIN: US0311621009
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Market cap
$177.71B
P/E
22.89
Forward P/E
14.81
Profit margin
20.96%
Revenue growth QoQ
5.80%
Div. yield
2.92%
Beta
0.43
$442.24 -0.36%
Price as of 2026-08-25 · NASDAQ

Performance by timeframe

Rolling returns
1 Month +18.22%
6 Months +16.61%
1 Year +56.95%
5 Years +18.34% p.a.+131.93%
10 Years +13.27% p.a.+247.44%
Since inception +9.80% p.a.+933.03%
Calendar year returns
YTD +37.88%
2025 +29.67%
2024 -6.77%
2023 +13.46%
2022 +20.43%
2021 +0.89%

Key stats

Market cap
177.71B
P/E
22.89
Dividend yield
2.92%
Beta
0.43
52-week range
253.48 - 391.29
50-day MA
353.55
200-day MA
325.47
Section 1

Business overview

Company profile data from fundamentals.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NASDAQ
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 1.01%
ROA 8.35%
Profit margin 20.96%
Operating margin 33.80%
PEG ratio 2.18
Revenue/share TTM 69.12
Revenue TTM 37.22B
EBITDA 16.92B
Gross profit TTM 26.59B
Beta 0.43

Valuation

Trailing P/E 22.89
Forward P/E 14.81
P/B 19.37
P/S 4.77
EV/EBITDA 13.39
EV/Revenue 6.00

ESG Scores

Total ESG 20.9
Environment 1.5
Social 15.1
Governance 5.8
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 22.41
Quarterly earnings growth 4.40%
Revenue TTM 37.22B
Reported quarters 121
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 2.92%
Forward annual div. yield 3.45%
Dividend per share 9.6600
Payout ratio 43.05%
Ex-dividend date 2025-08-22
Next dividend date 2026-06-05
Split factor 2:1
Last split date 1999-11-22
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $311.46
Analyst rating 3.625

Ownership & short interest

Shares outstanding 538.36M
Shares float 536.99M
Institutional ownership 84.15%
Insider ownership 21.40%
Short ratio 4.66
Short % of float 2.36%

Details

Instrument metadata and source update timestamps.

Symbol AMGN
Name Amgen Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US0311621009
Country USA
Code + exchange AMGN.NASDAQ
Last price date 2026-05-08
Fundamentals updated 2026-05-08

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.